Improvement of early‐phase insulin secretion is an independent factor for achieving glycaemic control: A pooled analysis of SEED and DAWN study
Authors' conclusion
Restoring the impaired early-phase insulin secretion function in patients with type 2 diabetes mellitus is a critical factor for improving the glycaemic control by dorzagliatin treatment.
Study context
- Population
- Patients with T2D treated in the SEED and DAWN studies414 on dorzagliatin
- Participants
- 726 patients
- Comparison
- Dorzagliatin vs placebo
- Dorzagliatinn = 414
- Outcome
- Association of early-phase insulin secretion (IGI30min, DI) with achieving glycaemic control
- Follow-up
- 24 weeks
Methodological detailslogistic regression analysis
- Logistic regression analysis
Pooled result
As reported in the abstract
Achieving glycaemic control (logistic regression)
OR for baseline IGI30min
1.28
95% CI 1.14–1.43
OR for 24-week incremental IGI30min from baseline
1.24
95% CI 1.14–1.35
OR for baseline disposition index (DI)
1.39
95% CI 1.2–1.6
OR for 24-week change in DI from baseline
1.30
95% CI 1.19–1.43
Further pooled results
Correlation of HbA1c reduction with IGI30min improvement · 24 weeks
- Significant correlation with dorzagliatin
- P < 0.001
- Correlation not observed with placebo
- P = 0.364
Responders vs non-responders (dorzagliatin)
- Responders showed significant improvements in HOMA2-β, IGI30min and DI vs non-responders
Postprandial glucose control
- OR for incremental IGI30min
- 1.3 (95% CI 1.19-1.42)
- OR for IGI2h
- 1 (95% CI 1-1.01)
- Early-phase rather than late-phase insulin secretion contributed significantly
Original publication
Improvement of early‐phase insulin secretion is an independent factor for achieving glycaemic control: A pooled analysis of SEED and DAWN study. Diabetes Obes Metab. Published 20 November 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →